Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into a definitive “reverse merger” agreement with Qualigen, Inc. (“Qualigen”), a privately-held company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform, whereby a wholly-owned subsidiary of the Company will merge with and into Qualigen in an all-stock transaction with Qualigen.
Read the full article: Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement //
Source: https://www.globenewswire.com/news-release/2020/01/21/1973035/0/en/Ritter-Pharmaceuticals-Inc-and-Qualigen-Inc-Announce-Merger-Agreement.html